Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?
In the surgical multimodal management of malignant pleural mesothelioma, it seems crucial to proceed with an efficient local adjuvant treatment to kill residual tumor cells. Intrapleural photodynamic therapy has recently emerged as a potential candidate in this goal. In this review, we analyzed and classified 16 articles in which patients with malignant pleural mesothelioma received intrapleural photodynamic therapy after maximal surgical resection. The toxicity, effect on survival, and development of the technique were assessed. After two decades of clinical studies, intrapleural photodynamic therapy after surgical resection became a safe treatment that significantly improved the survival of patients.
INSERM U703, Loos, France.
Camille
C
Munck
INSERM U703, Loos, France.
Serge R
SR
Mordon
Department of Pulmonary and Thoracic Oncology, Calmette Hospital, Lille, France.
Arnaud
A
Scherpereel
Department of Thoracic Surgery, Calmette Hospital, Lille, France.
Henri
H
Porte
Department of Pulmonary and Thoracic Oncology, Calmette Hospital, Lille, France.
Xavier
X
Dhalluin
INSERM U703, Loos, France. Electronic address: nacim.betrouni@inserm.fr.
Nacim
N
Betrouni
D006801:Humans; D007267:Injections; D008175:Lung Neoplasms / Q000188:drug therapy*; D008654:Mesothelioma / Q000188:drug therapy*; D000086002:Mesothelioma, Malignant; D010778:Photochemotherapy / Q000379:methods / Q000639:trends*; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D035422:Pleural Cavity; D010997:Pleural Neoplasms / Q000188:drug therapy*
D017319:Photosensitizing Agents